P285. Pharmacological Effects of the Novel NR2B Modulator Bi 1569912 on Electroencephalography and Eye-Tracking in a Phase I Study

BI 1569912 is a negative allosteric modulator of NR2B subunit-containing N-methyl-D-aspartate (NMDA) receptors, under development as a treatment for major depressive disorder. Safety, tolerability and food-dependent bioavailability were investigated in a Phase I study conducted at a single site in Germany (Charité, Berlin). Electroencephalography (EEG) and eye-tracking were measured as treatment-response biomarkers to evaluate central target engagement by BI 1569912.